|
86 Companies |
|
137 Products |
|
137 Products |
|
85 Mechanisms of Action |
|
4 Trials |
|
2019 News |
|
| «12...678910111213141516...3940» |
- Enrollment open, Enrollment change, Trial initiation date, Trial primary completion date: Mental Health and Cognitive Dysfunction: A Multicenter Study at Pediatric Rehabilitation Clinics in North Norway (clinicaltrials.gov) - Jul 9, 2015
P=N/A, N=320, Recruiting, Sponsor: University Hospital of North Norway
Not yet recruiting --> Recruiting | N=100 --> 320 | Initiation date: Jan 2013 --> Oct 2012 | Trial primary completion date: Dec 2013 --> Jun 2016
- Enrollment open, Trial initiation date: Exercise and Cognitive Training (clinicaltrials.gov) - Jul 8, 2015
P0, N=30, Recruiting, Sponsor: Boston University
Not yet recruiting --> Recruiting | N=100 --> 320 | Initiation date: Jan 2013 --> Oct 2012 | Trial primary completion date: Dec 2013 --> Jun 2016 Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> May 2015
- olanzapine / Generic mfg., amisulpride / Generic mfg.
Trial primary completion date, Monotherapy: COMBINE: Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy (clinicaltrials.gov) - Jul 2, 2015
P4, N=399, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
Not yet recruiting --> Recruiting | Initiation date: Jan 2015 --> May 2015 Trial primary completion date: Jun 2015 --> Aug 2016
- Aristada once-monthly (aripiprazole lauroxil once-monthly formulation) / Alkermes, Aristada two-month (aripiprazole lauroxil XR) / Alkermes
Enrollment closed: An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia (clinicaltrials.gov) - Jul 2, 2015
P1, N=140, Active, not recruiting, Sponsor: Alkermes, Inc.
Trial primary completion date: Jun 2015 --> Aug 2016 Recruiting --> Active, not recruiting
- AVL-3288 / Anvyl
Trial primary completion date: Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects (clinicaltrials.gov) - Jul 1, 2015
P1, N=80, Recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> May 2016
- Disalcid (salsalate) / Bausch Health
Enrollment closed, Trial initiation date: Salsalate as an Adjunctive Treatment for Patients With Schizophrenia (clinicaltrials.gov) - Jul 1, 2015
P4, N=15, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
Trial primary completion date: May 2015 --> May 2016 Recruiting --> Active, not recruiting | Initiation date: Dec 2011 --> Jun 2011
- Trial completion, Enrollment change, Trial primary completion date: Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients (clinicaltrials.gov) - Jul 1, 2015
P1, N=12, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | Initiation date: Dec 2011 --> Jun 2011 Recruiting --> Completed | N=100 --> 12 | Trial primary completion date: Jun 2016 --> Oct 2005
- Trial primary completion date: Contingency Management for Smoking Cessation Among Veterans With Psychotic Disorders (clinicaltrials.gov) - Jun 26, 2015
P=N/A, N=23, Terminated, Sponsor: Department of Veterans Affairs
Recruiting --> Completed | N=100 --> 12 | Trial primary completion date: Jun 2016 --> Oct 2005 Trial primary completion date: Jun 2013 --> Dec 2012
- |||| Trial completion: A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia (clinicaltrials.gov) - Jun 25, 2015
P4, N=353, Completed, Sponsor: Xian-Janssen Pharmaceutical Ltd.
Trial primary completion date: Jun 2013 --> Dec 2012 Active, not recruiting --> Completed
- ||||| Caplyta (lumateperone) - Intra / Cellular Therapies
Enrollment closed, Trial primary completion date: A Trial to Assess the Antipsychotic Efficacy of ITI-007 (clinicaltrials.gov) - Jun 24, 2015
P3, N=450, Active, not recruiting, Sponsor: Intra-Cellular Therapies, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Jul 2015
- Bydureon (exenatide XR once-weekly) / AstraZeneca
Trial completion: TAO: Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue (clinicaltrials.gov) - Jun 24, 2015
P3, N=45, Completed, Sponsor: Bjorn H. Ebdrup
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Jul 2015 Recruiting --> Completed
- Trial completion: IBASC: Improving Basic and Social Cognition in Veterans With Schizophrenia (clinicaltrials.gov) - Jun 24, 2015
P=N/A, N=72, Completed, Sponsor: Department of Veterans Affairs
Recruiting --> Completed Suspended --> Completed
- Trial completion: Influence of Acupuncture on Emotional Measures and Quality of Sleep Among Schizophrenia Patients (clinicaltrials.gov) - Jun 23, 2015
P=N/A, N=21, Completed, Sponsor: HaEmek Medical Center, Israel
Suspended --> Completed Active, not recruiting --> Completed
- ||| olanzapine / Generic mfg., amisulpride / Generic mfg., clozapine / Generic mfg.
Enrollment change: OPTIMISE: Optimization of Treatment and Management of Schizophrenia in Europe (clinicaltrials.gov) - Jun 22, 2015
P4, N=500, Recruiting, Sponsor: Rene Kahn
Active, not recruiting --> Completed N=350 --> 500
- Trial completion, Enrollment change, Trial primary completion date: NeSSy: Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia (clinicaltrials.gov) - Jun 22, 2015
P4, N=149, Completed, Sponsor: University of Bremen
N=350 --> 500 Recruiting --> Completed | N=630 --> 149 | Trial primary completion date: Apr 2012 --> Aug 2013
- Enrollment closed: Clinical Monitoring to Facilitate Continuous Care for Substance Abusing Clients (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=175, Active, not recruiting, Sponsor: Treatment Research Institute
Recruiting --> Completed | N=630 --> 149 | Trial primary completion date: Apr 2012 --> Aug 2013 Recruiting --> Active, not recruiting
- || Enrollment closed: CM ETG: Contingency Management of Alcohol Abuse in the Severely Mentally ILL (clinicaltrials.gov) - Jun 18, 2015
P=N/A, N=120, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Rykindo (risperidone extended release microspheres) / Luye Group
Trial completion: An Randomized Open-Label PK Study of LY03004 Compared to Risperdal (clinicaltrials.gov) - Jun 18, 2015
P1, N=16, Completed, Sponsor: Luye Pharma Group Ltd.
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed
- Trial primary completion date, Adherence: Effectiveness of Adherence Therapy for Schizophrenia (clinicaltrials.gov) - Jun 17, 2015
P1/2, N=134, Recruiting, Sponsor: The Hong Kong Polytechnic University
Enrolling by invitation --> Completed Trial primary completion date: May 2015 --> Aug 2015
- | risperidone / Generic mfg., paliperidone extended release / Generic mfg.
Enrollment closed, Enrollment change: A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia (clinicaltrials.gov) - Jun 16, 2015
P4, N=17, Active, not recruiting, Sponsor: Johnson & Johnson Taiwan Ltd
Trial primary completion date: May 2015 --> Aug 2015 Recruiting --> Active, not recruiting | N=50 --> 17
- || Trial primary completion date: Effects of a Walking Program in People With Mental Disorders (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=100, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Active, not recruiting | N=50 --> 17 Trial primary completion date: Dec 2014 --> Dec 2015
- || sodium valproate / Generic mfg.
Trial primary completion date: Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P4, N=100, Enrolling by invitation, Sponsor: University of Pittsburgh
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Feb 2015 --> Feb 2016
- Trial primary completion date: Cognitive Remediation of Schizophrenia in a Community Mental Health Setting (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=120, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Feb 2015 --> Feb 2016 Trial primary completion date: May 2015 --> Nov 2015
- Trial primary completion date: Cognitive Remediation for First Episode of Psychosis Patients (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=48, Recruiting, Sponsor: University of Manchester
Trial primary completion date: May 2015 --> Nov 2015 Trial primary completion date: Mar 2015 --> Jul 2015
- valacyclovir / Generic mfg.
Trial primary completion date: Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P4, N=156, Enrolling by invitation, Sponsor: University of Pittsburgh
Trial primary completion date: Mar 2015 --> Jul 2015 Trial primary completion date: Feb 2015 --> Nov 2015
- Trial primary completion date: Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=72, Recruiting, Sponsor: National Institute of Mental Health (NIMH)
Trial primary completion date: Feb 2015 --> Nov 2015 Trial primary completion date: Jul 2017 --> Jul 2015
- || Trial primary completion date: CM ETG: Contingency Management of Alcohol Abuse in the Severely Mentally ILL (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=120, Recruiting, Sponsor: University of Washington
Trial primary completion date: Jul 2017 --> Jul 2015 Trial primary completion date: Dec 2014 --> Sep 2015
- Trial primary completion date: Multi-disciplinary Treatment for Patients Experiencing First Episode of Psychosis (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=65, Active, not recruiting, Sponsor: Research Foundation for Mental Hygiene, Inc.
Trial primary completion date: Dec 2014 --> Sep 2015 Trial primary completion date: Jun 2013 --> Jan 2015
- || Byetta (exenatide) / AstraZeneca
Trial primary completion date: Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults (clinicaltrials.gov) - Jun 11, 2015
P4, N=60, Active, not recruiting, Sponsor: University of Cincinnati
Trial primary completion date: Jun 2013 --> Jan 2015 Trial primary completion date: Feb 2015 --> Jul 2015
- Trial primary completion date: Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis (clinicaltrials.gov) - Jun 11, 2015
P1/2, N=100, Recruiting, Sponsor: University of California, San Francisco
Trial primary completion date: Feb 2015 --> Jul 2015 Trial primary completion date: Mar 2015 --> May 2016
- aripiprazole / Generic mfg., risperidone / Generic mfg.
Trial primary completion date: Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis (clinicaltrials.gov) - Jun 11, 2015
P4, N=242, Active, not recruiting, Sponsor: North Shore Long Island Jewish Health System
Trial primary completion date: Mar 2015 --> May 2016 Trial primary completion date: Feb 2014 --> Dec 2014
- bupropion sustained-release / Generic mfg.
Trial termination: Extended Duration Nicotine Replacement Therapy and Bupropion in Smokers With Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P4, N=17, Terminated, Sponsor: Massachusetts General Hospital
Trial primary completion date: Feb 2014 --> Dec 2014 Completed --> Terminated
- Trial termination: FROPS: Functional Rehabilitation for Older Patients With Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=107, Terminated, Sponsor: Department of Veterans Affairs
Completed --> Terminated Completed --> Terminated; Loss of funding
- Trial initiation date, Trial primary completion date: Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=50, Not yet recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Completed --> Terminated; Loss of funding Initiation date: Nov 2014 --> Sep 2015 | Trial primary completion date: Dec 2015 --> Dec 2016
- Trial initiation date, Trial primary completion date: SPA: A System for Preference Assessment in Mental Health (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=95, Not yet recruiting, Sponsor: University of California, Los Angeles
Initiation date: Nov 2014 --> Sep 2015 | Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: Aug 2014 --> Jul 2015 | Trial primary completion date: Jul 2015 --> Dec 2015
- Enrollment change, Trial primary completion date: CAST: Optimizing Cognitive Remediation Outcomes in Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=160, Recruiting, Sponsor: University of California, San Francisco
Initiation date: Aug 2014 --> Jul 2015 | Trial primary completion date: Jul 2015 --> Dec 2015 N=80 --> 160 | Trial primary completion date: Apr 2015 --> Dec 2015
- ||| Trial completion: Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P1, N=68, Completed, Sponsor: University of North Carolina, Chapel Hill
N=80 --> 160 | Trial primary completion date: Apr 2015 --> Dec 2015 Active, not recruiting --> Completed
- Chantix (varenicline) / Pfizer
Enrollment change: Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal (clinicaltrials.gov) - Jun 4, 2015
P4, N=0, Withdrawn, Sponsor: VA Boston Healthcare System
Active, not recruiting --> Completed N=30 --> 0
- acetylcysteine solution / Generic mfg.
Trial completion: NACSZ: N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia (clinicaltrials.gov) - Jun 4, 2015
P1, N=26, Completed, Sponsor: VA Greater Los Angeles Healthcare System
N=30 --> 0 Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: Yoga as Cognitive Remediation in Schizophrenia (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=258, Active, not recruiting, Sponsor: Dr. Ram Manohar Lohia Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015
- ||| Trial completion, Enrollment change: Life Quality and Health in Patients With Klinefelter Syndrome (clinicaltrials.gov) - Jun 3, 2015
P=N/A, N=452, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Dec 2015 Enrolling by invitation --> Completed | N=1350 --> 452
- |||| Trial completion: Helping Those With Mental Illness Quit Smoking (clinicaltrials.gov) - Jun 2, 2015
P4, N=272, Completed, Sponsor: University of Wisconsin, Madison
Enrolling by invitation --> Completed | N=1350 --> 452 Active, not recruiting --> Completed
- Trial completion: Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia (clinicaltrials.gov) - May 29, 2015
P2, N=19, Completed, Sponsor: Federal University of Rio Grande do Sul
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment open, Trial primary completion date, Adherence: SPERA-S: Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia (clinicaltrials.gov) - May 28, 2015
P=N/A, N=280, Recruiting, Sponsor: University of Cagliari
Recruiting --> Completed Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2013 --> Jun 2015
- | acetylcysteine oral / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: NACPSY: N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis (clinicaltrials.gov) - May 28, 2015
P4, N=20, Completed, Sponsor: Beth Israel Deaconess Medical Center
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2013 --> Jun 2015 Recruiting --> Completed | N=33 --> 20 | Trial primary completion date: May 2014 --> Aug 2014
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment closed: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - May 27, 2015
P3, N=700, Active, not recruiting, Sponsor: FORUM Pharmaceuticals Inc
Recruiting --> Completed | N=33 --> 20 | Trial primary completion date: May 2014 --> Aug 2014 Recruiting --> Active, not recruiting
- | encenicline (EVP-6124) / Forum Pharmaceuticals, Mitsubishi Tanabe
Enrollment closed: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy (clinicaltrials.gov) - May 27, 2015
P3, N=700, Active, not recruiting, Sponsor: FORUM Pharmaceuticals Inc
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Trial completion: EXERCISE-II: Enhancing Synaptic Plasticity and Cognition in Schizophrenia (clinicaltrials.gov) - May 27, 2015
P=N/A, N=66, Completed, Sponsor: University Medical Center Goettingen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| asenapine / Generic mfg., olanzapine / Generic mfg.
Trial completion, Enrollment change: Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689) (clinicaltrials.gov) - May 27, 2015
P3, N=105, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=170 --> 105
- Trial completion: Factors Association With Poor Physical Function in Older Adults With Schizophrenia (clinicaltrials.gov) - May 27, 2015
P=N/A, N=46, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed | N=170 --> 105 Active, not recruiting --> Completed